Bio-Thera Solutions, News

Biotech U (688177): Good revenue growth, continuous implementation of overseas biosimilar licenses

China International Capital CorporationNov 5 08:12

Biotech (688177): Steady increase in revenue

Aug 26 19:36

Biotech (688177): 1H24 performance is in line with expectations, overseas licenses continue to be implemented

Aug 25 12:36

Baiaotai (688177): A pioneer of domestic biosimilar drugs going overseas with an innovative and international perspective

Jun 2 11:06

Biotech (688177): Steady progress in commercialization promotion around the world

May 13 14:31

Pacific released a research report on April 16 stating that it gave Biotai (688177.SH) a purchase rating. The main reasons for the rating include: 1) self-exemption and anti-tumor drugs drive rapid revenue growth; 2) multiple biosimilar drugs go overseas

Zhitong FinanceApr 16 10:14

Biotech (688177): Biosimilar drugs have entered the harvest period and the ADC pipeline continues to advance

Apr 9 07:51

Biotech (688177): Rapid growth of biosimilar drugs and the pipeline of innovative drugs is progressing smoothly

Apr 8 00:00

Biotech (688177): Similar drugs go overseas and enter the harvest period, and performance is expected to usher in a high increase

Apr 2 18:51

Biotech (688177): The global analog market is about to open up, and the potential for a new ADC platform can be expected

Jan 23 07:32

Biotech (688177): Biosimilar drugs going overseas are expected to enter a period of large-scale explosion

太平洋證券Sep 14, 2023 00:00

Biotech (688177): It is worth paying attention to when the products go overseas

財通證券Sep 4, 2023 00:00

Biotech (688177) 2021 Interim Report Review: Galleria's Sales Volume and R&D Pipeline Abundant

東方財富證券Sep 3, 2021 00:00

Biotech (688177) 2020 Report Review: Adalimumab Release Exceeds Expectations, Bevacizumab Is Expected to Be Commercialized This Year

東方財富證券Mar 11, 2021 00:00

Biotech (688177) In-depth research: focusing on biopharmaceutical research and development gradually entering a harvest period

東方財富證券Jan 5, 2021 00:00

N Biotech (688177): R&D drives China's leading biopharmaceutical platform

海通證券Feb 21, 2020 00:00

Biotech (688177) IPO Research Report: Biopharmaceutical Innovation Company Approved to Produce the First Domestic Adalimumab

中泰證券Feb 9, 2020 00:00

Science and Technology Innovation Board Subscription Strategy - Baiotai (688177)

國泰君安Feb 6, 2020 00:00